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Summary We describe here an improved method of encapsulating doxorubicin in liposomes using
phosphatidylcholine, cholesterol and synthetic tetramyristoyl cardiolipin. With this new composition of lipids
the entrapment of doxorubicin was found to be >90%. Cytotoxicity studies using vincristine-resistant HL-60/
VCR leukaemia cells showed that liposome-encapsulated doxorubicin reverses multidrug resistance 5-fold
compared with conventional doxorubicin and at levels equivalent to that obtained using liposomes with natural
cardiolipin. In normal mice, liposome-encapsulated doxorubicin was much less toxic than the conventional
drug. A dose of 25 mg kg-' i.v. of conventional doxorubicin produced 100% mortality in mice by day 14,
whereas liposomal doxorubicin exhibited only 10% mortality by day 60. Liposomal doxorubicin demonstrated
enhanced anti-tumour activity against murine ascitic L1210 leukaemia compared with conventional
doxorubicin. At a dose of 15 mg kg-', liposomal doxorubicin increased the median life span with 12 of 18
long-term (60 days) survivors compared with only 3 of 18 with conventional drug. Mice injected i.v. with
liposomal doxorubicin had plasma levels 44-fold higher than conventional doxorubicin, producing significantly
higher (P<0.02) area under the plasma concentration curve. An altered tissue distribution was also observed
with liposomal doxorubicin; cardiac tissue demonstrating at least 2-fold lower levels with liposomal
doxorubicin probably accounting for its lower toxicity. This altered pharmacokinetics ofliposome-encapsulated
doxorubicin, providing enhanced therapeutic advantage and the ability to modulate multidrug resistance, could
be useful in a clinical setting.
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The anthracycline antibiotics play a prominent role in the
treatment of leukaemia and solid tumours in humans. Among
this class of compounds, doxorubicin has shown significant
activity against a wide range of human cancers, including
leukaemia, lymphomas and a variety of solid tumours (Tan et
al., 1973; Frederickson et al., 1974). Unfortunately, the clinical
useofthe agent islimited by anunusualcardiomyopathy, which
is related to the total cumulative dose ofthe drug (Minow et al.,
1977). Doxorubicin also produces acute toxicity in the form of
bone marrowdepression, alopeciaandoralulceration (O'Bryan
et al., 1977).
New formulations of doxorubicin using liposomes as
delivery systems have been investigated to avoid treatment-
limiting side-effects and to achieve better therapeutic efficacy
(Forsen and Tokes, 1981; Gabizon et al., 1982; Gregoriadis et
al., 1974; Olson et al., 1982; Rahman et al., 1980). Previously,
our laboratory showed that encapsulation of doxorubicin
into liposomes prepared from cardiolipin, egg phosphatidyl-
choline, cholesterol and stearylamine was less toxic than
conventional doxorubicin in mice and beagle dogs (Herman
et al., 1983; Rahman et al., 1985). At the same time,
liposome-encapsulated doxorubicin (LED) had equivalent or
greater anti-tumour activity than conventional doxorubicin
against various murine tumour models (Rahman et al.,
1986a). Subsequently, LED was used for the phase I and
phase II clinical trials (Rahman et al., 1990; Treat et al.,
1990). LED was found to be well tolerated and demonstrated
significant anti-tumour activity in patients with recurrent
breast cancer (Treat et al., 1990). Intraperitoneally adminis-
tered LED was also found to be safe and effective in patients
with ovarian cancer (Delgado et al., 1989).
Despite the encouraging clinical results observed in
patients, further studies with LED could not be carried out
primarily because of the problems related to the successful
scale-up of the liposomes. Also the entrapment of doxor-
ubicin into these liposomes was low (45-55%), requiring
time-consuming processes to remove the unentrapped
doxorubicin. Therefore, in order to improve the entrapment
efficiency, we changed the liposome composition as well as
substituting natural cardiolipin with synthetic tetramyristoyl
cardiolipin. As the chemical composition, charge, structure
and mode of preparation are all known variables that can
modify the physicochemical, biological and pharmacological
properties of the liposomes and therefore of the encapsulated
drug, the present study was undertaken to evaluate the new
liposomal doxorubicin formulation for its modulation of
multidrug resistance, safety, efficacy and pharmacokinetic
behaviour in animals.
Materials and methods
Chemicals
Doxorubicin was purchased from Adria Laboratories
(Columbus, OH, USA) and egg phosphatidylcholine and
cholesterol from Avanti Polar Lipids (Alabaster, AL, USA).
1,1',2,2'-Tetramyristoyl cardiolipin, synthesised by Avanti
Polar Lipids was a generous gift. All other chemicals were
reagent grade.
Animals
Male CD2F1 mice and female DBA/2 mice, 8-10 weeks old,
20-25 g were purchased from the National Cancer Institute
(Frederick, MD, USA). Mice were maintained according to
accredited procedures in our facility, and fed purina chow
and water ad libitum.
Correspondence: A Rahman, Georgetown University Medical
Center, Department of Radiology, Preclinical Science Building,
Room GD-9, 3900 Reservoir Road, Washington, DC 20007, USA
Received 22 June 1995; revised 30 October 1995; accepted 7
December 1995Improved liposomal preparation of doxorubicin
PC Gokhale et a!
44
Cell cultures
The murine ascitic L1210 cell line was obtained from the
Animal Genetics Branch, Developmental Therapeutics
Program, Division of Cancer Treatment, National Cancer
Institute, Frederick, MD, USA. The L1210 leukaemia was
maintained by serial intraperitoneal (i.p.) passage in female
DBA/2 mice.
HL-60 promyelocytic leukaemic cells were obtained from
the American Type Culture Collection (Rockville, MD,
USA). The vincristine-resistant subline HL-60/VCR (ob-
tained from Dr Melvin Center), which expresses the
multidrug resistance phenotype was maintained in suspen-
sion culture with 2,M vincristine (McGrath and Center,
1988). Cultures were grown as suspensions in RPMI-1640
medium (Gibco Laboratories, NY, USA) supplemented with
10% heat-inactivated fetal bovine serum, 2 mM glutamine
and penicillin/streptomycin. Cell lines were maintained at
37°C under 95% relative humidity in an atmosphere
containing 5% carbon dioxide. The vincristine-resistant
subline was maintained in drug-free medium for at least 1
week before study.
Preparation of liposomes
1,1',2,2'-Tetramyristoyl cardiolipin, phosphatidylcholine and
cholesterol in a molar ratio of 1:10:6.8 were dissolved in
chloroform-methanol (2:1) mixture and dried in a rotating
flask under vacuum. Doxorubicin (1 mg ml-1), in sterile
normal saline was added to the dried lipid film. The drug to
lipid molar ratio was 1:10. The film was hydrated and
dispersed by vigorous vortexing. The hydrated suspension
was sonicated for 30 min in a bath type sonicator (Heat
Systems, W380) to yield small unilamellar liposomes. In
separate experiments, lipids were lyophilised and doxorubicin
in saline was added. The mixture was allowed to hydrate for
1 h and then sonicated to obtain small unilamellar liposomes.
The unincorporated doxorubicin was separated from
liposomally entrapped drug by extensive dialysis against
sterile normal saline at 4°C over a period of 20 h or by gel
chromatography using Sephadex G-50. The amount of
doxorubicin encapsulated in liposomes was determined by
fluorescence measurement (470 nm, excitation; 580 nm,
emission). In all the experiments, the concentration of
doxorubicin encapsulated in liposome was equivalent to the
concentration of free drug used. The size of the liposomes as
determined by flow cytometry was found to be less than
0.5 ,um. Blank liposomes were prepared using the same
composition of lipids in the absence of doxorubicin; they
were diluted in sterile saline to yield lipid doses equivalent to
those of liposome-encapsulated doxorubicin.
Cytotoxicity assay
The growth-inhibition method was used to determine the
cytotoxicity of conventional doxorubicin and LED in human
promyelocytic leukaemia cells. In brief, 5 x 104 HL-60 and
HL-60/VCR cells were plated in tissue culture cell wells (well
diameter 35 mm, Corning, NY, USA). Cells in exponential
growth were exposed to varying concentrations of doxor-
ubicin or LED for 72 h at 37°C. Cells were then counted in a
haemocytometer, and viability was determined by trypan blue
dye exclusion. The data is expressed in terms of IC50, which
corresponds to the concentration of the drug resulting in
50% survival of the cells compared with control.
Toxicity evaluation
For the comparison of lethal toxicity of conventional
doxorubicin and LED, normal CD2F1 male mice received
single i.v. doses of 15, 20 and 25 mg kg-'. The mice were
observed until day 60 after drug administration. The control
mice received either saline or blank liposomes representing
the same concentration of the lipid as was used to entrap a
dose of 25.0 mg kg-' doxorubicin. Mice in each group were
weighed and observed daily.
In vivo antitumour activity study
For in vivo anti-tumour studies, male CD2F1 mice were
injected i.p. on day 0 with 1 x 105 viable L1210 leukaemia
cells. On day 1, they were randomly divided into groups of
ten mice. Each group received varying doses of either
conventional doxorubicin or LED administered i.p. Control
groups received saline or blank liposomes i.p. The injection
volume was 2% body weight (0.2 ml 10 g-' body weight).
Survival was recorded every 24 h and the mice were
evaluated until day 60.
Pharmacological disposition studies
For pharmacological studies, male CD2F1 mice were injected
i.v. via the tail vein with 6 mg kg-1 of either conventional
doxorubicin or LED. At 5 min, 15 min, 1 h, 2 h, 4 h, 8 h and
24 h after drug administration, four mice in each group were
bled from the retro-orbital sinus into heparinised tubes and
were killed by cervical dislocation. The blood was centrifuged
at 2000 r.p.m. for 10 min at 4°C to separate the plasma. The
liver, spleen, kidney, lung, heart and small intestine were
rapidly excised and rinsed in ice-cold normal saline. The
organs and plasma were frozen at -20°C until assayed for
doxorubicin.
Plasma and tissue samples were analysed for doxorubicin
by the method as pseviously described (Rahman et al.,
1986b). Plasma (0.25 ml) was diluted to 1 ml with distilled
water, followed by addition of 0.2 ml of silver nitrate (33%,
w/v). Tissues were homogenised in 1 ml of distilled water in a
Polytron homogeniser (Brinkmann Instruments, Westbury,
NY, USA) followed by addition of 0.2 ml of silver nitrate.
The tubes were vortexed and 3 ml of n-butyl alcohol
saturated with water was added. Each tube was vortexed
vigorously for 1 min and then centrifuged at 5000 r.p.m. for
10 min. The organic layer was removed followed by further
extraction of residue with 2 ml of n-butyl alcohol. The two
extracts were pooled and doxorubicin was assayed spectro-
fluorometrically at 470 nm excitation and 580 nm emission.
Control plasma and tissue samples obtained from mice
treated with normal saline or blank liposomes were
processed similarly to correct for any endogenous fluores-
cence. Standards were prepared by spiking known concentra-
tions of doxorubicin in blank plasma and tissue to calculate
the concentration of doxorubicin in samples.
Plasma pharmacokinetic parameters were assessed by
standard methods (Gibaldi and Perrier, 1982). The elimina-
tion rate constant (,B) was calculated from the linear
regression analysis of plasma concentration vs time curve.
The area under the curve (AUCO,,) was calculated using the
linear trapezoidal method with extrapolation of the terminal
phase to infinity (Clast/f where Clast is the last measured
concentration. Other parameters calculated were as follows:
Total body clearance (Cl)=Dose/AUC; volume of distribu-
tion (Varea)=Cl/#; elimination half-life (t112f)=0.693/fl.
Statistical methods
The statistical significance of difference between means was
calculated by Student's t-test. The Wilcoxon rank-sum test
was used to compare group median survival. Differences in
end point survival between conventional doxorubicin and
LED was analysed by chi-square test. A P<0.05 was
considered to be statistically significant.
Results
Encapsulation efficiency of liposomes
The encapsulation of doxorubicin into liposomes prepared
using phosphatidylcholine, cholesterol and 1,1',2,2'-tetramyr-Improved liposomal preparation of doxorubicin
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istoyl cardiolipin by conventional methods, was found to be
greater than 90% (n=20). In other experiments, lipids were
lyophilised and then reconstituted with doxorubicin solution
in saline. In all these experiments, more than 90%
encapsulation of doxorubicin was also observed (n=20).
In vitro cytotoxicity
The concentration of conventional doxorubicin that caused
50% growth inhibition (IC50) in the parent HL-60 cells after 3
days of exposure was 10.5 ng ml-', whereas it was
0.412 ,ug ml-1 in HL-60/VCR cells. Hence, HL-60/VCR
cells with multidrug resistance phenotype were 39-fold
resistant to doxorubicin. When liposomal doxorubicin was
used, the IC50 for HL-60 cells was 7.5 ng ml-', which was
similar to conventional doxorubicin. However, liposomal
doxorubicin showed a 4.7-fold potentiation in cytotoxicity to
HL-60/VCR cells compared with conventional doxorubicin
(P<0.001); the IC50 being 0.088 jug ml-1 (Figure 1). Blank
liposomes had no cytotoxic effects on either HL-60 or HL-60/
VCR cells.
In vivo toxicity
Various groups of normal CD2F1 mice received single i.v.
injections of either conventional doxorubicin or LED at
doses of 25.0, 20.0 and 15.0 mg kg-'. Animals receiving
conventional doxorubicin at a dose of 25.0 mg kg-1 exhibited
100% mortality by day 13 (Table I). However, animals
receiving a 25.0 mg kg-' dose of liposomal doxorubicin
demonstrated only 10% mortality, with 90% of the animals
surviving until the end of the study. At a dose of
20.0 mg kg-', 60% mortality was observed by day 27 with
conventional doxorubicin, whereas no mortality was observed
in the group of animals receiving the same dose of liposomal
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doxorubicin. Conventional doxorubicin at a dose of
15.0 mg kg-' produced 20% mortality in mice by day 60,
while no mortality was observed with the same dose of drug
entrapped in liposomes.
Variation in body weight was recorded in all groups of
mice treated with either conventional drug or liposomal
doxorubicin. The mice treated with saline or blank liposomes
had a progressive increase in body weight. Mice treated with
25 mg kg-' conventional doxorubicin had a rapid weight
loss, amounting to 19% by day 6. Mice that received
25.0 mg kg-1 LED had a maximum weight loss of 14% until
day 10; with a progressive weight gain after day 10 (data not
shown).
In vivo activity
To determine the anti-tumour activity of doxorubicin
entrapped in liposomes, studies were carried out against the
murine L1210 ascitic leukaemia in CD2F1 mice (Figure 2).
Twenty-four hours after i.p. implantation of 1 x 105 L1210
tumour cells, mice were given i.p. injections of conventional
doxorubicin or doxorubicin entrapped in liposomes in
varying doses. A dose of 15 mg kg-' was most effective
with both types of treatment. The median survival time with
conventional doxorubicin was 16.5 days and there were 3 of
18 long-term survivors. Treatment with LED significantly
increased the anti-tumour activity (P<0.001) and there were
12 of 18 long-term survivors.
Table I Toxicity evaluation of conventional doxorubicin and
liposome encapsulated doxorubicin in CD2F1 mice
Dose Median survival (days) Sixty day survival(%)
(mg kg-) Dox LED Dox LED
15.0 >60 >60 80 100*
20.0 25.5 >60 40 100*
(10-60)
25.0 7.0 >60 0 90*
(6-13)
CD2F1 mice received single i.v. injection of conventional doxor-
ubicin (Dox) or liposome-encapsulated doxorubicin (LED). At each
dose level groups consisted often animals. The numbers in parenthesis
represents range. *P< 0.001.
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Figure 1 Cytotoxicity of doxorubicin and liposome-encapsulated
doxorubicin in HL-60 (a) and HL-60/VCR cells (b). Cells were
exposed with conventional doxorubicin (0) or doxorubicin
encapsulated in liposomes (0) for 72h and cytotoxicity was
determined by growth inhibition assays as described in Materials
and methods. Each value is the mean+s.d. of three experiments
carried out in duplicate.
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Figure 2 Anti-tumour efficacy of conventional doxorubicin
(= ) and doxorubicin encapsulated in liposomes (x) against
L1210 murine leukaemia in CD2F1 mice. Mice were inoculated
i.p. with 1 x 105 L1210 cells and treated with varying doses of
drug administered i.p. 24h after tumour implantation. Values
over each bar (alive/number of animals treated) represent long-
term survival (60 days). The median survival time of control
group treated with either saline or blank liposomes (n=24) was
7.5 days. Also shown is the interquartile range, indicated by error
bars, between the 25th percentile and the 75th percentile.
*P<0001.Improved liposomal preparation of doxorubicin
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Pharmacokinetics
The plasma pharmacokinetics of conventional doxorubicin
and liposome-encapsulated doxorubicin in mice at a dose of
6 mg kg-1 is presented in Figure 3. Following i.v. adminis-
tration of conventional doxorubicin, the peak plasma
concentration achieved was 0.867 pg ml-'. On the other
hand, with liposomes, the peak plasma concentration of
doxorubicin achieved was 38.04 pg ml-', which was 43.8
times more than conventional doxorubicin. The comparative
pharmacokinetic parameters obtained after a single i.v. bolus
administration of conventional doxorubicin and doxorubicin
entrapped in liposomes are presented in Table II. LED
produced significantly higher (P<0.02) area under the
plasma-concentration-time curve compared with conven-
tional doxorubicin. The calculated volume of distribution at
steady state was substantially reduced with LED as compared
with conventional doxorubici
ubicin clearance was also mai
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Figure 3 Plasma concentratioi
tional doxorubicin (0) and
liposomes (0). Male CD2F1
6mgkg-1 dose of conventic
encapsulated doxorubicin and
equivalents were determined
methods. Each point represents
The tissue distribution of conventional doxorubicin and
doxorubicin entrapped in liposomes is presented in Table III.
The peak cardiac concentration with conventional doxor-
ubicin was 16.9 pg g-1 at 15 min, whereas it was 7.7 pg g-'
at 5 min with liposomal doxorubicin. The cardiac tissue
concentration of doxorubicin after administration of LED
was at least 2-fold less (P<0.001) than conventional drug,
and this relationship was maintained over 8 h. The liver and
spleen demonstrated significantly higher (P<0.001) accumu-
lation of LED compared with conventional doxorubicin.
Drug levels in the small intestine showed a modest decrease
with LED, but no significant difference was seen in the area
under the curve.
Discussion
in, and calculated total doxor- This reportdescribes a newmethod ofpreparation ofliposome-
rkedly reduced (P<0.01). encapsulated doxorubicin with greater simplicity that makes
the scale-up of these liposomes much easier. Cardiolipin, a
diphosphatidylglycerol containing two negative charges, has
been shown to have a high affinity for doxorubicin, which
contains one positive charge. In our previous study with
liposome-encapsulated doxorubicin (Rahman et al., 1985), the
liposomes were composed ofcardiolipin, phosphatidylcholine,
cholesterol and a positively charged stearylamine. In these
studies, the low entrapment of doxorubicin was because of
interaction of stearylamine with cardiolipin. Elimination of
stearylamine from the liposomal preparation mixture was
associated with increased doxorubicin entrapment. With this
new formulation the entrapment ofdoxorubicin was found to
be >90%. In separate experiments, we found that by simply
mixing and vortexing conventional drug with lyophilised lipids,
:1_ 1 _1 r __1-:__1
12 18 24 similar level ot- encapsulati-on could be achieved. l'his
12me 18h2 procedure of preparing liposomes can simplify the industrial
Time (h) manufacturing process and make this drug available to patients
for treatment. As shown previously (Thierry et al., 1994), the
complex formation between doxorubicin and cardiolipin is
In time relationshp for conven- strongly stabilised by electrostatic interaction between two
mice were injected i.v with a molecules of doxorubicin and one molecule ofcardiolipin and a
)nal doxorubicin or liposome- stoichiometric interaction which leads to a card-pack dimer
plasma levels of doxorubicin formation (Goormaghtigh and Ruysschaert, 1984). In this
as described in Materials and study, we have replaced natural cardiolipin, which has a
a mean+s.d. of four animals. heterogenous fatty acid structure with synthetic cardiolipin, a
Table II Pharmacokinetic parameters of conventional doxorubicin and liposomal doxorubicin in
CD2Fl mice after single i.v. dose of 6 mg kg-'
tip AUC0o Cl Vare_ (A) (jig h mr ) (ml h-' kg-l) (I kg- )
Conventional doxorubicin 12.6 ±0.4* 3.19+0.5* 1902.4±286.7** 34.7 ±6.4**
Liposomal doxorubicin 8.8+0.8 32.5+6.9 188.6 +39.6 2.4+0.7
Values are means±s.d. tip, elimination half-life; AUC, area under the plasma-concentration-time
curve; Cl, total body clearance; Varea, volume ofdistribution; *P<0.02, **P<0.01.
Table III Tissue distribution of doxorubicin after i.v. administration of 6 mg kg-l of conventional doxorubicin or liposome-encapsulated
doxorubicin
Heart Liver Spleen Lungs Kidneys Small intestine
Time Dox LED Dox LED Dox LED Dox LED Dox LED Dox LED
5 min 14.8+± 1.8 7.7+0.9 54.8+2.6 47.2+2.7 19.2+5.3 58.7+8.5 24.1+3.4 8.6+0.9 36.1+6.1 12.2+0.7 4.5+2.5 1.1 ±0.2
15 min 16.9+0.5 7.2+1.2 57.0+4.8 56.3+4.8 14.1+3.7 85.4+5.9 20.3+1.611.5+1.7 28.9+2.0 11.8+0.5 5.3+1.9 1.3+0.3
1 h 10.9+2.4 4.9+0.7 25.1+3.1 53.9±11.3 13.4+1.2 139.6+19.6 19.6+2.6 6.0+1.5 22.7+2.5 11.4+2.5 1.2+0.7 0.7+0.2
2 h 9.5+0.9 3.2+0.6 27.1+4.8 57.7+6.6 13.5+0.8 117.5+22.6 14.5+3.4 5.2+0.7 25.5+5.2 10.2+1.1 1.4+0.3 0.8+0.4
4 h 6.4+0.5 2.8+0.2 24.7+3.0 51.0+4.9 13.7+1.4 156.7+18.7 14.1+0.2 5.0+0.4 21.0+3.8 10.5+0.9 1.1+0.8 0.7+0.2
8 h 3.9+0.4 1.9+0.1 15.7+1.8 51.5+2.8 17.1+1.6 172.1+15.3 10.2+1.2 4.2+0.5 17.6+0.8 8.6+1.5 0.6+0.3 0.6+0.2
24 h 1.5+0.1 1.3+0.1 3.9+0.5 18.3+2.5 13.9+1.1 179.5+16.3 6.3+1.1 6.5+0.5 6.0+0.6 5.0+0.9 0.4+0.1 0.2+0.1
AUCO24 103.6 52.1* 356.3 979.4* 364.0 3980.0* 245.8 128.7* 371.8 191.0* 18.9 12.6
(pghg-') +10.4 +4.4 +43.4 +80.4 +32.9 +372.8 +29.1 + 13.4 +33.4 +27.7 +8.2 +4.3
Values aremeans+s.d. offourmice(ugg- tissue). Dox,conventional doxorubicin; LED, liposome-encapsulated doxorubicin; AUC, areaunder
the curve. P<0.001.
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well-defined molecule, to further improve the scale-up and
minimise the batch to batch variations. This study was
undertaken to determine whether (1) synthetic cardiolipin
modulates multidrug resistance (MDR) in human cancer cells
as previously observed and (2) that the improved liposomal
preparation ofdoxorubicin has toxicologicaL pharmacological
and therapeutic advantages as compared with conventional
doxorubicin.
A majorproblem in thechemotherapy ofsolid tumours and
haematological malignancies is the intrinsic as well as acquired
cross-resistance to multiple chemotherapeutc agents (Biedler
and Riehm, 1970; Dano, 1973). This type of MDR has been
related to overamplification of a gene, mdrl, and its over-
exprssed geneproduct, p-glycoprotein, in auncercells (Juliano
and Ling, 1976; Kartner et al., 1985; Morrow and Cowan,
1988). The p-glycoprotein has been shown to function as an
efflux pump that prevents accumulation of drugs and alters
their cytotoxicity in cancer cells (Gottesman and Pastan, 1988;
Horio et al., 1988). Recently, extensive studies from our
laboratory have demonstrated that liposome-encapsulated
doxorubicin effectively modulates the MDR phenotype in
cancer cells by altering the function of p-glycoprotein. The
liposomes were shown to bind specifically to p-glycoprotein,
which was demonstrated by inhibiting the photoaffinity
labelling ofazidopine to the p-glycoprotein. This binding was
associated with enhanced cellular drug accumulation and
altered drug distribution inside the MDR-expressing cells
(Thierry et al., 1989; Oudard et al., 1991; Rahman et al.,
1992; Thierryetal., 1993). Themodulation ofMDRphenotype
by liposomes has been shown in vitro in a number of human
cancer cell lines (Thierry et al., 1989; Oudard et al., 1991;
Rabman et al., 1992; Thierry et al., 1993) and in vivo in
transgenic mice (Mickisch et al., 1992) transfected with a
functional human mdrl gene. The present study demonstrates
that LED modulates multidrug resistance in HL-60/VCR cells
and thismodality oftreatment enhances thecytotoxicity nearly
5-fold as compared with conventional doxorubicin. These
observations support the hypothesis that substitution of
natural cardiolipin with synthetic cardiolipin maintains the
capacity ofliposomes to modulate MDR.
The goal of using liposomes as a drug-delivery system
involves a high concentration and/or long duration of
action at a target site, where beneficial effects may occur
while maintaining a low concentration and/or reduced
duration at other sites, where adverse effects may occur.
Such an objective requires altering the organ distnbution of
the drug substantially. Much of the work on liposomes has
been focused on cancer treatment as conventional cancer
therapy has been far from satisfactory. Liposomes
encapsulating a variety of anti-cancer agents have been
shown to enhance anti-tumour activity, decrease toxicity
and alter in vivo tissue distribution (Kim, 1993). In the
present study, doxorubicin encapsulated in liposomes
prepared from phosphatidylcholine, cholesterol and syn-
thetic cardiolipin was found to significantly alter the specific
tissue distribution of the drug in mice as compared with
conventional drug. These altered disposition characteristics
were found to be associated with significant reduction in the
lethal toxicity of liposome-encapsulated doxorubicin. The
concentration of drug in cardiac tissue was at least 2-fold
lower following administration of LED compared with
conventional doxorubicin. LED was also found to be more
effective in the treatment of the murine L1210 leukaemia
model. In summary, this study demonstrates that the new
liposomal formulation with synthetic cardiolipin as its
integral component is beneficial for overcoming multidrug
resistance and provides enhanced therapeutic advantages
over conventional doxorubicin. We believe that these
preclinical findings support evaluation of this LED
preparation in clinical trials.
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